11 July 2024
Cambridge Cognition Holdings
plc
(ÒCambridge CognitionÓ, the ÒCompanyÓ or the
ÒGroupÓ)
Cambridge Cognition secures
Innovate UK grant for Bio-Hermes 2 project
Cambridge Cognition Holdings plc
(AIM: COG), which develops and markets digital solutions to assess
brain health, is pleased to have been selected to provide voice and
touchscreen cognitive assessments for the Global AlzheimerÕs Platform FoundationÕs Bio-Hermes 2 project. Cambridge Cognition is receiving
grant funding from Innovate UK, the UKÕs innovation agency (as
included in the announcement dated 29 May 2024). Three of Cambridge
CognitionÕs CANTABª touchscreen cognitive tasks, measuring working
memory, episodic memory and processing speed, and a Winterlight
speech and language task will be used.
The Bio-Hermes
2 project aims to generate a world-leading
dataset to improve the understanding
of how digital and blood-based biomarkers can be
used to predict the extent of AlzheimerÕs Disease pathology
as detected by positron emission tomography
(PET) brain scans. 1,200 patients covering
the clinical spectrum of the disease, from normal
ageing to mild cognitive impairment and through to dementia,
will be monitored for up to 24
months.
With such a sizeable sample of
patients over a long period, the project will generate a large
dataset that will considerably add to the existing
scientific evidence for the CompanyÕs voice and touchscreen assessments. In particular, it will be
the first large dataset that the Company will have using both
CANTAB and Winterlight assessments, providing an opportunity to
have combined assessments for patients in the future to better address emerging needs in AlzheimerÕs Disease drug
development.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
commented:
"We are delighted that our CANTAB and Winterlight solutions
will be in the Bio-Hermes 2 project and are grateful to Innovate UK
for the funding. This could be a groundbreaking study for Cambridge
Cognition, and indeed for the clinical field, as it could enable
the company to be the first to provide a combined all-in-one voice
and touchscreen assessment for AlzheimerÕs disease in the
futureÕ.
Enquiries:
Cambridge Cognition Holdings
plc
Matthew Stork, Chief Executive
Officer
Stephen Symonds, Chief Financial
Officer
|
Tel: 012 2381
0700
|
Panmure Liberum Limited (NOMAD and
Joint Broker)
Freddy Crossley / Emma
Earl
Rupert Dearden
|
Tel: 020 7886
2968
(Corporate
Finance)
(Corporate
Broking)
|
Dowgate Capital Limited (Joint
Broker)
David Poutney / James
Serjeant
|
Tel: 020 3903
7715
|
Hudson Sandler (Financial PR and
IR)
Dan de Belder / Hattie
Dreyfus
|
Tel: 020 7796
4133
cog@hudsonsandler.com
|
|
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology
company developing digital health products to better understand,
detect and treat conditions affecting brain health. The Company's
software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients
early and improve global efficiency in pharmaceutical and
healthcare industries.
For further information
visit: https://cambridgecognition.com/